Oncology

FDA Approves Treatment for Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma

The FDA has approved venetoclax for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

Gilteritinib Proves Promising for the Treatment of FLT3mut + Acute Myeloid Leukemia

Planned analyses of phase 3 trial of gilteritinib as a maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML).

Combination Therapy Holds Promise for Newly Diagnosed Systemic AL Amyloidosis Patients

Updated research regarding the ANDROMEDA study indicates the efficacy of subcutaneous daratumumab (DARA SC) and cyclophosphamide, bortezomib, and dexamethasone (CyBorD) as a combination therapy in newly diagnosed light chain (AL) amyloidosis patients.

Gene Sequencing Connects Lynch Syndrome with Other Cancers

Study suggests a link between Lynch syndrome (LS) and more cancer types than previously thought.

Phase 2 Trial Initiates Dosing of Selective Translation Regulator in Non-GCB DLBCL Patients

The first patient has been dosed in the phase 2 expansion portion of its monotherapy trial of eFT508 for the treatment of relapsed, refractory non-germinal center B cell (non-GCB) diffuse large B cell lymphoma (DLBCL).

Ultrasound Device Shows Efficacy for Recurrent Glioblastoma in Phase 1 Trial

Phase 1/2a clinical trial (NCT02253212) data on ultrasound-induced blood-brain barrier (BBB) opening for brain disorders like recurrent glioblastoma.

Treatment for Ultra-Rare Neuroendocrine Cancers Shows Efficacy in Phase 2 Trial

Iobenguane I 131 (AZEDRA) has been shown to be effective in patients with malignant, recurrent, or unresectable pheochromocytoma and paraganglioma (pheo/para).

A Family Affair: Multiplex Germline Testing in Melanoma

Pauline Funchain MD, explains her research which focuses on assessing possible underlying genetic and familial factors in melanomas.

Benefits of Brentuximab Vedotin & Chemotherapy Combination for Advanced Stage Hodgkin Lymphoma

Radhakrishnan Ramchandren MD, highlights the recent US Food and Drug Administration’s (FDA) approval and advantages of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for advanced stage, classic Hodgkin lymphoma.

EZH2 Inhibitor Well-Tolerated in Relapsed/Refractory Malignant Mesothelioma Patients

Researchers present promising phase 2 data regarding tazemetostat for malignant mesothelioma, the first reported clinical data of an EZH2 inhibitor in these patients.

<< Prev Page

Next Page >>